Abstract: The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.

Abstract: The present invention relates to a nanoformulated self-assembled pharmaceutical composition for photodynamic therapy. More particularly, the present invention is directed to a self-assembled pharmaceutical composition for photodynamic therapy comprising a photosensitizer, a ligand A which is separated at a specific pH range, and a ligand B of which surface charge changes at a specific pH range and a method for manufacturing the same.

Abstract: The present invention relates to a novel oral pharmaceutical composition in the form of a stable flocculated suspension in water, said composition comprising micronized megestrol acetate at a concentration of 10 to 200 mg per ml, polysorbate at a concentration of 0.01% to 12.6% weight by volume, or polyethylene glycol at a concentration of about 0.01% to 5.0% weight by volume, polyoxyl 35 castor oil at a concentration of 0.05% to 51.5% weight by volume and/or polyoxyl 40 hydrogenated castor oil at a concentration of 0.05% to 45% weight by volume in a stable flocculated suspension in water. The composition also may include preservatives, sweeteners, pH adjusting agents and flavoring agents.

Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.

Abstract: The invention relates generally to ephedrine or pseudoephedrine compositions containing biocompatible organoleptic (food flavoring) excipients that would prevent the illicit manufacture of methamphetamine from ephedrine or pseudoephedrine.

Abstract: A potency-extending agent of a botulinum toxin type-A product includes 1 ml of distilled water, 85 of dextrose, 4.28 mg of sodium chloride, and 10 mg of trehalose.

Abstract: A composition used in the treatment of the cold sores is composed of Water, Propylene Glycol, Mineral Oil, Behenyl Alcohol or docosanol, Benzocaine, Vitamin E tocopheryl, Sucrose Stearate, and Benzyl Alcohol.

Abstract: There are provided a lyophilized preparation of botulinum toxin without a protein stabilizer derived from animals. The lyophilized preparation of botulinum toxin according to the present invention can maintain an activity of botulinum toxin, and also exhibit excellent long-term storage stability even under conditions of high temperature, which may occur when botulinum toxin is stored, delivered, and processed.

Abstract: A drug carrier includes an aqueous solution, a protein shell, graphenes, and a bioactive agent. The protein shell encloses the aqueous solution, and includes at least one hydrophilic/hydrophobic layer. The graphenes are dispersed in the protein shell, and the bioactive agent is in the aqueous solution and/or the protein shell.

Abstract: A polymeric composition capable of releasing nitric oxide and modulating biological responses comprises a biocompatible polymer and S-nitrosated thiol bonded to the biocompatible polymer. The polymeric composition can have a thiol conversion of at least 40%. The polymeric composition can also have a nitric oxide recovery of at least 40% when under thermal decomposition conditions.

Abstract: The present disclosure relates to a new polymerisation process in which ethylenically unsaturated monomers are polymerised by a living radical polymerisation process in the presence of an initiator and a catalyst. Polymers produced by this new process are also thought to be novel and may be used to derivatise biological molecules to improve their efficacy as therapeutic treatments. A preferred polymer is of formula The polymers are particularly suitable for derivatising proteins, such as interferon-?.

Abstract: The present invention relates to a process for the preparation of a hydrogel suitable as carrier in a hydrogel-linked prodrug, to hydrogels obtainable from said process, the use of such hydrogel as a carrier in a hydrogel-linked prodrug and to hydrogel-linked prodrugs comprising a covalently conjugated hydrogel of the present invention. The hydrogel prodrug carrier has a reduced drug loading on the outside of the hydrogel carrier. This is achieved by reducing the number of functional groups of the hydrogel, in particular those at its surface.

Abstract: A cell-penetrating peptide characterized in that it comprises an amino acid sequence X3X4X1X2X5X4X1X2X6X7X1X8X9X10X11X12X13 (SEQ ID No: 11), wherein X1 is F or W, X2 is F, W or Y, X3 is beta-A or S, X4 is K, R or L, X5 is E, R or S, X6 is R. T or S, X7 is E, R or S, X8 is none, F or W, X9 is P or R, X10 is R or L, X11 is K, W or R, X12 is R or F and X13 is R or K.

Abstract: A cascade carrier linked prodrug is described comprising a biologically active moiety and a masking group having at least one nucleophile and being distinct from the carrier.

Abstract: The present invention concerns methods and compositions for treatment of HIV infection in a subject, utilizing a DNL complex comprising at least one anti-HIV therapeutic agent, attached to an antibody, antibody fragment or PEG. In a preferred embodiment, the antibody or fragment binds to an antigen selected from gp120, gp41, CD4 and CCR5. In a more preferred embodiment the antibody is P4/D10 or 2G12, although other anti-HIV antibodies are known and may be utilized. In a most preferred embodiment, the anti-HIV therapeutic agent is a fusion inhibitor, such as T20, T61, T651, T1249, T2635, CP32M or T-1444, although other anti-HIV therapeutic agents are known and may be utilized. The DNL complex may be administered alone or may be co-administered with one or more additional anti-HIV therapeutic agents.

Abstract: The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moiety is preferably directed against tumour-associated antigens. In particular, the amatoxin is conjugated to the antibody by linker moieties. In particular the linker moieties are covalently bound to functional groups located in positions of the amatoxin proved as preferred positions for the attachment of linkers with respect to optimum antitumor activity. In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer.

Abstract: In certain embodiments, the present disclosure provides compositions and methods for treating Forbes-Cori Disease.

Abstract: Normal or genetically modified cell(s) having magnetic nanoparticle(s) bound (affixed) to their surfaces and methods of delivery to target tissues, e.g. For treatment of disease and/or injury.

Abstract: The instant disclosure provides RNA-modulating agents that function to recruit one or more small regulatoryRNA molecules (e.g., miRNA molecules, Y RNAs, and siRNAs) to a target mRNA thereby modulating (e.g., inhibiting) the translation of the target mRNA or destabilizing the mRNA. Also provided are miRNA inhibitors and diagnostic agents that have improved binding affinity for their target miRNAs. Methods for using the RNA-modulating agents, miRNA inhibitors and diagnostic agents are also provided.

Abstract: The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body.

Abstract: The present invention relates to MRI contrasting agent for contrasting cancer cell which contains ultrafine nanoparticles. More particularly, the present invention is directed to a self-assembled ligand composition comprising a ligand A, which is separated at a specific pH range, and a ligand B of which surface charge changes at a specific pH range, MRI contrast agent for contrasting cancer cell comprising said ligand composition and MRI contrasting nanoparticles, and the methods for preparing them.

Abstract: Targeted microbubbles are generated by post-labeling buried ligand microbubbles. According to embodiments, buried ligand microbubbles are created with steric brushes protecting functionalized polymer tethers. Ligands were attached to the functionalized tethers by diffusion of ligands of a small size through the steric barrier. The steric barrier was substantially capable of hindering access to the tethers by larger molecules. The embodiments disclosed include methods for creating microbubble batches that can be loaded with selected ligands, for titrating the targeting ligands thereby to reduce waste and cost, and for using resulting buried ligand molecules for medical purposes.

Abstract: A UV device includes a housing having a portion configured to be removably attached to a smart device, a UV light source disposed within the housing, wherein the UV light source is configured to provide output of UV light in response to an operating powered, a communication mechanism disposed within the housing, wherein the communication mechanism is configured to receive instructions from the smart device, a control mechanism disposed within the housing, wherein the control mechanism is coupled to the UV light source, and to the communication mechanism, wherein the control mechanism is configured to provide the operating power to the UV light source, in response to the instructions received from the smart device.

Abstract: A method for a smart-device comprising receiving a user selection of an icon on a display, initiating acquisition of a first image of a target surface using a camera in response to receiving the selection, directing power to an UV-LED disposed proximate to the camera, wherein the power is provided to the UV-LEDs for less than about 0.5 seconds, while power is provided to the UV-LED, initiating acquisition of a second image of a target surface using the camera, determining an image visually highlighting a contaminant on the target surface in response to the first and second images, determining an object type associated with the target surface, in response to the first image, determining geographic data, and storing the image, the object type, and the geographic data in a memory.

Abstract: Embodiments relate generally to systems and methods for treating passenger transportation vehicle cabin surfaces and surrounding air. The methods may use organic LEDs to produce ultraviolet light. Systems may be provided to ensure safety and operation of the air treatment only when passengers and personnel are not present in the cabin.

Abstract: Disclosed herein is a detergent pourer sterilizer. In one aspect, a detergent pourer sterilizer is provided to include a housing including a hollow portion having an open side; a detergent pourer configured to be detachably attached to the housing; a cover member configured to open or close the one open side of the hollow portion; and at least one UV LED configured to emit ultraviolet light toward the hollow portion.

Abstract: The shoe sole sanitizer provides a UV radiation emitting system that kills microbial pathogens deposited on shoe sole surfaces. The system includes a housing containing at least one UV radiation source. Bottom and side portions of the housing are opaque to provide a UV shield while directing the UV upward towards a top housing portion. The top housing portion has a plurality of holes forming an approximate shape of two shoe sole bottoms. The holes allow the UV radiation to escape the housing and target sole surfaces disposed on and over the exterior of the housing top. Each shoe sole approximation area has a pivotal tang that extends therefrom. Shutters attached internally to the tangs extend or limit UV exposure from the top surface depending on the size of the sole disposed on the top. The system is powered by standard AC electrical power or battery sources.

Abstract: The present invention relates to freshening compositions and devices comprising same that comprise a composition having a viscosity of from about 1 mPa·s to about 50,000 mPa·s comprising malodor reduction compositions and methods of making and using such compositions. The disclosed malodor reduction compositions do not unduely interfere with the scent of the freshening compositions and devices that comprise such technologies and the perfumed or unperfumed situs that is treated with such freshening compositions and devices.

Abstract: A sanitization system for sanitizing a convey line broadly includes an ozone generation and delivery module, a compressed air source, and an air flow control system, and an ozone measurement and destruction module. The ozone generation and delivery module includes ozone generator, an ozone flow meter, a first ozone analyzer, a humidifier, and a humidity sensor and introduces a measured ozone gas stream into the convey line so that the ozone disinfects the inner surfaces of the convey line. The humidifier introduces moisture into the convey line to increase the effectiveness of the ozone as a disinfection agent. The ozone measurement and destruction module includes a second ozone analyzer, an ozone destructor, and an ozone monitor and removes ozone from the gas stream. The ozone measurement and destruction module also ensures that a desired amount of ozone reaches the end of the convey line.

Abstract: The present invention relates to malodor reduction compositions and methods of making and using same. The malodor reduction compositions are suitable for use in a variety of applications, including use in consumer products, for example, air freshening compositions, laundry detergents, fabric enhancers, surface cleaners, beauty care products, dish care products, diapers, feminine protection articles, and plastic films for garbage bags. Such malodor control technologies do not unduely interfere with the scent of the perfumed or unperfumed situs that is treated with the malodor control technology.

Abstract: The present invention relates to freshening compositions and devices comprising same that comprise a composition comprising malodor reduction compositions and methods of making and using such compositions. Such malodor control technologies do not unduely interfere with the scent of the perfumed or unperfumed situs that is treated with the malodor control technology.

Abstract: An apparatus for producing a fragrance from a solid fragrance carrier is presented. The apparatus includes a heating element; a base positionable adjacent the heating element, the base having an upper end and a lower end; and a retainer member operable to contain the solid fragrance carrier and positionable adjacent the upper end of the base.

Abstract: A volatile substances evaporation device comprises a body (1) which can house an element (2) impregnated with volatile substances; an electric resistance (4); and a plug (5) for connection to a power grid; and said electrical resistance (4) is positioned in said plug (5) and said plug (5) is movable with respect to said body (1) so that the distance between the element (2) and said electrical resistance (4) is variable, defining at least one position of maximum evaporation and one position of minimum evaporation.

Abstract: Described are modulating coatings that are configured to provide an improved release profile of a volatile composition from a base material, wherein the modulating coating includes a barrier substance that is configured to hinder a release of the volatile composition through the modulating coating, and a hygroscopic substance that is configured to facilitate the release of the volatile composition through the modulating coating.

Abstract: A composition containing a malodor counteracting compound and a method for using the compound for counteracting a malodor in air space or a substrate is provided.

Abstract: Described is an ion air purifier. The ion air purifier includes a collector module (1) and a repeller module (2) which are connected in an openable and closable manner, wherein several collector plates (11) are uniformly distributed on the collector module (1), and several repeller plates (21) are uniformly distributed on the repeller module (2); and each collector plate (11) and each repeller plate (21) are alternately arranged when the two plates are in a closed state. Thus, an optimized distance between adjacent collector plates (11) and repeller plates (21) is ensured; and when the collector module (1) and the repeller module (2) are in an opened state, the collector plates (11) are separated from the repeller plates (21), and the distance between two adjacent collector plates (11) and the distance between two adjacent repeller plates (21) are both increased, thereby facilitating cleaning of the collector module. Further described is a network air purifier.

Abstract: Sheet for cutaneous application comprising a support layer made of loosely woven fabric embedded in a layer of silicone elastomer incorporating vitamin E or an ester thereof, wherein the layer of silicone elastomer has a thickness less than or equal to 2.0 mm and the silicone elastomer contains an elasticity modifier consisting of a triglyceride of saturated C8-C18 fatty acids.

Abstract: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.

Abstract: The present invention provides a system comprising: (i) a layer containing a nitrite; and (ii) a hydrogel that contains hydrogen ions; wherein the layer containing a nitrite and/or the hydrogel comprises a pharmaceutically active agent. The invention also provides the use of a system of the invention in medicine, and in the treatment of pain.

Abstract: Provided is a collagen sponge which has compressive strength (stress) equivalent to that of a tissue into which the collagen sponge is to be implanted, has no unevenness in structure and stress, and has a pore structure for allowing cells to infiltrate thereinto. The collagen sponge is obtained by subjecting a collagen dispersion, a collagen solution, or a mixture thereof having a collagen concentration of 50 mg/ml or more to freeze-drying and insolubilization treatment thereafter. The collagen sponge thus obtained has a stress of from 10 kPa to 30 kPa when loaded with 10% strain, has in its surface and inside a pore structure having a mean pore diameter ranging from 50 ?m to 400 ?m, and has a pore diameter standard deviation equal to or less than 80% of the mean pore diameter.

Abstract: Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers. The macromolecular matrix may include a crosslinked combination of hyaluronic acid and collagen.

Abstract: Provided are hybrid biomaterials comprising one or more layers of cross-linked poly(propylene fumarate) and/or cross-linked copolymer comprising a plurality of cross-linked propylene fumarate moieties. The layers may further comprise a plurality of microparticles, a plurality of micropores, or both a plurality of microparticles and a plurality of micropores encapsulated within the cross-linked poly(propylene fumarate) and/or cross-linked copolymer comprising a plurality of cross-linked propylene fumarate moieties. One of the layers is disposed on a compliant matrix dense tissue substrate (e.g., a pericardium tissue substrate). The hybrid biomaterials can be used, for example, in method of repairing tissue defects.

Abstract: The invention disclosed herein is directed to a porous wound healing foam composition that is made from an extracellular matrix of a mammal, method of making, and method of using.

Abstract: The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair, and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement. In certain embodiments, compounds disclosed herein are useful for managing obesity and diabetes or other metabolic syndromes by modulation of brown fat.

Abstract: The present disclosure relates generally to coating medical devices. In particular, the present disclosure provides materials and methods for coating a portion of a balloon catheter with a pharmaceutical agent using electrodeposition techniques. Although angioplasty and stenting can be effective methods for treating vascular occlusions, restenosis remains a pervasiveness problem. Therefore, coating portions of a balloon catheter with a pharmaceutical agent that inhibits restenosis can reduce the likelihood of restenosis.

Abstract: Embodiments of the invention include medical device elements formed from polymers with lubricious properties. In an embodiment, a method of forming a medical device element is included. The method can include mixing a first polymeric component and a second polymeric component to form a polymer mixture. The method can further include forming the polymer mixture into the medical device element. The method can also include treating the polymer mixture with at least one of an acid or a base. In an embodiment, a medical device is included. The medical device can include a lubricious element, the lubricious element comprising a mixture of a first polymeric component and a second polymeric component. The second polymeric component can include a polymer that is treated with at least one of an acid or a base after formation of the element. Other embodiments are also included herein.

Abstract: A medical device intended for contact with living tissue comprises a substrate having a surface, which surface comprises a layer comprising gallium oxide. A layer comprising a gallium oxide has been shown to inhibit biofilm formation on the surface of the medical device, which may reduce the risk for infection e.g. around a dental implant. A method of producing the medical device comprises: a) providing a substrate having a surface; and applying a gallium compound onto said surface to form a layer, preferably using a thin film deposition technique.

Abstract: A device for circulatory support of the heart with holding means implanted intracardially in the left or right ventricular outflow of the heart by catheter, using an endovascular method, through a femoral access or a percutaneous transventricular, transseptal, transapical or transvenous access, the holding means comprises anchoring means fixed in the subcommissural triangle underneath the aortic valve and the pulmonary valve, in the flow direction of the blood on the ventricular side of the aortic valve and the pulmonary valve, a pump fixed in the holding means by a catheter, using an endovascular method, through a femoral access or a percutaneous transventricular, transseptal, transapical or transvenous access, the pump can be inserted releasably into the holding means after the holding means has been fixed by the anchoring means in the subcommissural triangles underneath the aortic valve and the pulmonary valve, or is connected to the collapsible and expandable anchoring means.

Abstract: An extra-corporeal controller unit for an implantable ventricular assist device (VAD) includes control circuitry integrated with a rechargeable power source without including any power cables between the control circuitry and the rechargeable power source. The rechargeable power source includes two or more rechargeable batteries configured in respective battery modules. The battery modules are configured for removable installation in a housing of the controller unit. Mating power connectors are integrated in the battery modules and the housing. The mating connectors are configured to couple each battery to the control circuitry whenever the respective battery module containing the battery is installed in the housing. An energy storage unit may be permanently included in the controller unit and configured to remain fully charged and provide power to the VAD when the battery modules are removed.

Abstract: A pressure output device (POD) assembly for sensing fluid pressure in a fluid processing system, is provided. This POD assembly includes a shell defining a shell interior, and a movable diaphragm disposed in the shell interior and separating the shell interior into a flow-through chamber and a pressure sensing side. A sensor port is in fluid communication with the pressure sensing side. An inlet port and an outlet port are in fluid communication with the flow-through chamber. The inlet port and the outlet port define an inlet and an outlet, respectively, of a flow-through channel that passes through the flow-through chamber. A boss protrudes from the interior wall of the shell and extends into the flow-through channel to prevent occlusion of flow under different pressure conditions within the flow-through chamber.